Shelton Capital Management Purchases Shares of 3,442 Charles River Laboratories International, Inc. (CRL)

Shelton Capital Management purchased a new position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 3,442 shares of the medical research company’s stock, valued at approximately $348,000.

A number of other institutional investors also recently added to or reduced their stakes in the stock. Alps Advisors Inc. lifted its position in Charles River Laboratories International by 0.3% during the 2nd quarter. Alps Advisors Inc. now owns 5,350 shares of the medical research company’s stock worth $541,000 after acquiring an additional 14 shares in the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS lifted its position in Charles River Laboratories International by 0.5% during the 2nd quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 6,953 shares of the medical research company’s stock worth $703,000 after acquiring an additional 33 shares in the last quarter. Bbva Compass Bancshares Inc. lifted its position in Charles River Laboratories International by 0.8% during the 2nd quarter. Bbva Compass Bancshares Inc. now owns 6,004 shares of the medical research company’s stock worth $607,000 after acquiring an additional 50 shares in the last quarter. World Asset Management Inc lifted its position in Charles River Laboratories International by 2.2% during the 2nd quarter. World Asset Management Inc now owns 2,762 shares of the medical research company’s stock worth $279,000 after acquiring an additional 59 shares in the last quarter. Finally, M&T Bank Corp lifted its position in Charles River Laboratories International by 1.8% during the 2nd quarter. M&T Bank Corp now owns 4,358 shares of the medical research company’s stock worth $441,000 after acquiring an additional 76 shares in the last quarter. 95.38% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: This piece of content was reported by Ticker Report and is the property of of Ticker Report. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US and international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.tickerreport.com/banking-finance/2957300/shelton-capital-management-purchases-shares-of-3442-charles-river-laboratories-international-inc-crl.html.

Charles River Laboratories International, Inc. (CRL) opened at 112.59 on Friday. Charles River Laboratories International, Inc. has a 12 month low of $67.20 and a 12 month high of $113.83. The firm has a 50 day moving average price of $107.86 and a 200-day moving average price of $97.96. The firm has a market capitalization of $5.36 billion, a price-to-earnings ratio of 29.67 and a beta of 0.96.

Charles River Laboratories International (NYSE:CRL) last released its earnings results on Wednesday, August 9th. The medical research company reported $1.29 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.22 by $0.07. The firm had revenue of $469.13 million for the quarter, compared to analyst estimates of $458.25 million. Charles River Laboratories International had a return on equity of 27.02% and a net margin of 10.13%. The company’s revenue was up 8.1% on a year-over-year basis. During the same quarter last year, the firm posted $1.20 EPS. On average, equities analysts forecast that Charles River Laboratories International, Inc. will post $5.10 EPS for the current year.

In other Charles River Laboratories International news, insider Davide Molho sold 6,165 shares of the firm’s stock in a transaction that occurred on Thursday, October 5th. The stock was sold at an average price of $110.00, for a total value of $678,150.00. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider William D. Barbo sold 4,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 17th. The shares were sold at an average price of $99.91, for a total value of $399,640.00. Following the completion of the sale, the insider now directly owns 20,424 shares in the company, valued at approximately $2,040,561.84. The disclosure for this sale can be found here. Insiders sold a total of 22,529 shares of company stock worth $2,278,496 in the last ninety days. Insiders own 2.20% of the company’s stock.

Several research firms recently commented on CRL. Zacks Investment Research raised Charles River Laboratories International from a “hold” rating to a “buy” rating and set a $110.00 price target on the stock in a research report on Thursday, August 10th. Jefferies Group LLC boosted their price target on Charles River Laboratories International from $120.00 to $130.00 and gave the stock a “buy” rating in a research report on Monday. Royal Bank Of Canada began coverage on Charles River Laboratories International in a research report on Tuesday, September 19th. They set a “sector perform” rating and a $110.00 price target on the stock. BidaskClub raised Charles River Laboratories International from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, August 22nd. Finally, Barclays PLC reissued a “hold” rating and set a $102.00 price target on shares of Charles River Laboratories International in a research report on Wednesday, July 19th. Six analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the stock. Charles River Laboratories International has an average rating of “Buy” and an average target price of $100.50.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Institutional Ownership by Quarter for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2017 Ticker Report. Google+.